Member Info for Noise

ValJu; from what Roses has said so far, his allegiances and rivalries, there are a rather limited pool of persons and organisations he could be working for. Occam's razor suggests a rather obvious employer, although guessing his motivation is far tougher.

I can propose 1-2 theories, amusing to ponder them, perhaps one day I'll bother Satu and see if she can fill in the dots.

January/HardtoHandle - can you explain why there are two illiterate losers with identical grammatical styles and severe anti-Valirx biases?

Your welcome to stay and be negative on one account, but let's not use multiple sock puppet accounts please.

Anyone with half a brain who compared your posting history can see this.

Roses, I presume the trial at UCLH will finish this month, or plausibly next month, with initial verbal communications at least.

Many datasets will be easily digestable (PSA graphs, scans and physician feedback) will be relatively easy and quick to understand, possibly communicable in relatively short turnaround (probably not in June?).

Beyond that, formal reporting of the entire 4 year trial for peer review would likely take until November 2019? I am open to your opinion on this.

Uncanny, true, for once there are a number of decent bits of newsflow about to land in the world of Valirx. Nothing guaranteed yet, but plenty of datasets to arrive.

PS logan, not the greatest RNS, but functional as we expected it to cover the bases.

I suspect without the equity releases we'll drift up over June, I'll have to consider how I think developments will happen in July, as really we have to consider both good and not-very-ideal options for July, but definitely willing to stay holding until we hear something from 201.

Correct, yes far longer than I have kicked around (I probably turned up 2015 or so).

I think we spoke at length years ago, are you still doing the consulting work?

Marmited, naw, Roses is many things, but not linked to Blue Ocean.

I am hopeful we'll get something leftfield from VAL401 reasonably soon (if that JV/deal/partnership is ever going to come through, it should be coming through in the next couple of months). Not sure how it would be structured, hell if it comes through with £10m payment Valirx can have twice the MCAP. We're still at a tiddling value, so any remotely slight successes will suddenly triple the SP (or significantly more, £30m is not unheard of in biopharma land, especially with 201 in prostate/breast/ovarian cancer+ endometriosis, followed perhaps by 401 in multiple adenocarcinomas).

The MCAP is around £3m so it depends whether that offers enough risk/reward to enough investors. Maybe...just maybe, that inflection point is due.

My my my....

4 different trades at 0.51+

Am I allowed to say breakout? Pleasant reading

5 trade at 0.42-0.44p, looks like this morning will be another jump up

Key clinical trial data due to be reported to Valirx this month, no equity overhang for a few weeks. Traders could argue it's a technical big long - investors may think finally it's time to buy?

PM709, not sure where your live price data is from? Last three trades were 0.35, followed by 0.36 and 0.37p.

Ticking up at 0.37p. Are we looking at a sustained week of rises?

The important bit, in pre-clinical findings the main result was that 201 stops hormonally driven prostate cancers (and others, breast, ovarian etc.) from growing.

"An interim inspection of the trial's output indicates that the compound is and continues to perform as predicted from the pre-clinical findings."

Nom, the price dropped because there was a flood of equity dilution onto the market. There is currently no equity overhang, so there is a possibility of the price returning to normal levels. A technical long condition with added decent newsflow anticipated within the short term.

Roses, yes and no, I am more than aware the phase 1 trial got extended into phase 2, with a further dose escalation period beyond that.

As you are a chronic and persistent liar, you will well know they did not announce they were not extending the phase 2 trial last week. They said "ValiRx will either out-license the VAL201 asset to a major pharmaceutical company or will proceed to a pivotal Phase llb study." A slightly different statement.

Some very interesting market moves, now do I take a punt on lithium or go for solid, dependable oilco dividends.....

Official Title: A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Study Start Date: October 2014
Estimated Primary Completion Date: June 2019

Have a good weekend everyone x

See you all nice and early on Monday......June 3rd.

11% of the company traded in one morning. Looking forward to an interesting start on Monday.....

201 data nearly here. No share overhang. Technical long day!!!

Thanks for the insight keeptofacts. I would think that EHGO have sold their shares now, so there is unlikely to be a large overhang from them anymore?

If so, a modest rerate would be pleasant. Small steps....but I think we could nibble up to £6m MCAP?

Newsflow expected within weeks on a biopharma trial as well :)